children with acute myeloid leukaemia (AML) were treated in the MRC AML 10 trial. Three risk groups were identified based on cytogenetics and response to treatment. One hundred and twenty-five children relapsed -103 in the bone marrow only, 12 in the bone marrow combined with other sites, and six had isolated extramedullary relapses (site was not known in four cases). Eighty-seven children received further combination chemotherapy, one all-trans retinoic acid for acute promyelocytic leukaemia, and one a matched unrelated donor allograft in relapse, and 61 achieved a second remission. One patient with no details on reinduction therapy also achieved second remission. Treatment in second remission varied -44 children received a BMT (22 autografts, 12 matched unrelated donor allografts, 10 family donor allografts), and 17 were treated with chemotherapy alone. The overall survival rate for all children (treated and untreated) was 24% at 3 years, with a disease-free survival of 44% for those achieving a second remission. Length of first remission was the most important factor affecting response rates -children with a first remission of less than 1 year fared poorly (second remission rate 36%, 3 year survival 11%), whereas those with longer first remissions had a higher response rate (second remission rate 75%, 3 year survival 49%, P Ͻ 0.0001).
Introduction
Population-based studies have shown an improvement in the 5 year survival for children with acute myeloid leukaemia (AML) from 6% for those diagnosed from 1971 to 1974 to 40% for those diagnosed from 1984 to 1989, 1,2 primarily due to improved chemotherapy and supportive care. In the United Kingdom Medical Research Council (MRC) AML 10 trial, overall survival and disease-free survival for children under 15 years of age were 57% and 52% at 7 years. 3 Despite these improvements relapse remains the main cause of treatment failure and only a minority of these children are long-term survivors following further therapy. Several factors affecting the likelihood of survival following relapse, particularly length of first remission, have been identified from studies with adults [4] [5] [6] but there are limited data regarding children. 7 Accordingly, and as a basis for future studies, the outcome for those children who suffered a relapse following initial treatment in AML 10 is presented.
Materials and methods
Between courses of intensive chemotherapy; children with a matched sibling donor were then eligible for a bone marrow allograft (BMT) in first remission, while remaining children were eligible for randomisation between an autograft (ABMT) and no further therapy ( Figure 1 ). All children received four courses of 'triple' intrathecal chemotherapy (cytarabine, methotrexate and hydrocortisone), and cranial irradiation was reserved for those with CNS disease at diagnosis (defined as Ͼ5 white cells/mm 3 in the cerebrospinal fluid with recognisable blasts on CSF cytospin, or cranial nerve palsy). There was no single recommended strategy for the management of relapsed disease which was at the discretion of the treating physician, but details of children with relapse including further therapy, remission rates and outcome were obtained prospectively by standard trial forms. The length of first remission was calculated as the time from initial complete remission (CR) to first relapse, overall survival after relapse was the time from relapse to death, and disease-free survival was the time from second complete remission to any event (relapse or death). Surviving patients were censored on July 1 1998 when data were complete for over 97% of patients registered, and those children lost to follow-up were censored on the last date they were known to be alive. Median follow-up is 6.5 (range 3.3-10.1) years. Second CR rates were compared using the Mantel Haenzel test for trend and Fishers exact test (in 2 × 2 tables), and actuarial survival curves were calculated by the method of Kaplan and Meier. The effects of length of first remission and risk group on survival from relapse and disease-free survival were assessed by means of the log rank test. Outcomes after 2nd CR following chemotherapy alone, and chemotherapy plus BMT or ABMT were compared by Mantel-Byar analysis, which provides an adjustment to the log rank test to allow for the time to transplant.
Results
In children entered in AML 10 the complete remission rate was 93%, disease-free survival was 52%, and overall survival was 57% at 7 years. There were no differences in overall survival between treatment groups, but relapse was less common in children randomised to ABMT (31% vs 52% at 7 years, P = 0.03), and among those children with a bone marrow donor compared with no donor (30% compared with 45%, P = 0.02). Three risk groups (good, standard and poor) were identified based on cytogenetics, FAB type and the percentage of blasts in the bone marrow after one course of chemotherapy. 3 Good risk children (n = 89) had t(15; 17) or FAB type M3, t(8;21), or inversion 16. Standard risk children (n = 165) had responsive disease defined as Ͻ15% blasts in the bone marrow after recovery from the first course of chemotherapy, and neither favourable or unfavourable cytogenetics, while poor risk children (n = 58) had monosomy 7, monosomy 5, deletions of 5q, abnormalities of 3q, complex cytogenetics with four or more separate abnormalities, or resistant disease defined as Ͼ15% blasts in the bone marrow on recovery from course 1. The overall survival rates from first remission for these groups at 7 years were 79, 60 and 34%, respectively, while the disease-free survival rates were 59, 55 and 31%, respectively.
By July 1 1998, 125 children had relapsed at a median of 295 days from first remission, and relapse was most common in the first year (27%), with rates of 11, 3 and 1% for the second, third, and fourth years, respectively, with no relapses to date beyond 4 years. The bone marrow was the most common site of relapse (Table 1 ) and relapse in the central nervous system was very uncommon, occurring in only seven cases. Details of risk group were available for 120 relapsing children and relapse rates were 34% in the good risk group, 58% in the standard risk group, and 66% in the poor risk group. Adequate Table 1 Sites of relapse (n = 125) information regarding further treatment was available in 122 cases. Reinduction was attempted in 89 cases (87 children were treated with combination chemotherapy, one was given all-trans retinoic acid (ATRA) for acute promyelocytic leukaemia (AML M3) and one child received a matched unrelated donor allograft in relapse). Care was not aimed at achieving second CR in 33 (10 single agent, 23 palliation) patients. A further four children received transplants in relapse (two BMT, two ABMT) when reinduction chemotherapy failed. There was no significant difference in length of first remission between children receiving further intensive therapy or palliative care only (P = 0.09). Reinduction was attempted in 89% of good risk patients but only in 68% of standard risk and 60% of poor risk patients (trend P = 0.02). For children given combination chemotherapy, 48 received re-induction with standard courses from AML 10, while 39 were treated with other multi-agent regimens (Table 2) , including sequential high-dose cytarabine and asparaginase (CLASP, n = 3) 8 or fludarabine, high-dose cytarabine, and granulocyte colonystimulating factor (FLAG, n = 8). 9 The number of courses of chemotherapy given varied from one to three, with a median of two courses. The child with AML M3 entered second remission following ATRA, but the other 10 children receiving single agent therapy did not remit. Three children who received transplants in relapse remitted (one BMT and one ABMT following courses of chemotherapy and one child who received a matched unrelated donor allograft rather than chemotherapy). Among the 87 children treated with combination chemotherapy, 59 entered second remission, the majority after one course (range 1-3 courses), Table 2 Response to reinduction therapy Small numbers and lack of randomised allocation to treatments precludes comparisons between regimens. ADE, cytarabine, daunorubicin, etoposide; DAT, daunorubicin, cytarabine, thioguanine; MACE, amsacrine, cytarabine, etoposide; FLAG, fludarabine, cytarabine, G-CSF; MidAC, mitoxantrone, cytarabine; ATRA, all-trans retinoic acid; CLASP, cytarabine, asparginase. giving an overall remission rate in children receiving reinduction therapy of 69% (61/89). Among 11 children who received reinduction chemotherapy following an ABMT or BMT in first remission four entered second remission, three following multiple drug combinations, and one following ATRA. One of the three children with missing reinduction therapy data also achieved second remission. Treatment in second remission varied -44 children received a bone marrow transplant (22 ABMT, 12 unrelated donor BMT, 10 family donor BMT -nine full match, one HLA mismatch), and 17 were treated with chemotherapy alone. Two children received a second high-dose procedure (both BMT) following a transplant in first CR. There were a median of two (range 1-3) courses of chemotherapy given prior to transplant and the procedures were performed at a median of 67 (range 1-289) days from second remission. Children who received a BMT had significantly longer first remissions than those treated by chemotherapy only (Wilcoxon two sample test P = 0.0001).
The overall survival from relapse for all 125 children was 24% at 3 years with a disease-free survival of 44% for the 62 children who entered second remission (Figures 2 and 3) , at a median follow-up at the time of analysis of 1303 (range 329-2238) days from second remission. Twenty-nine have achieved remission inversion (second remission longer than first remission), 26 following BMT. Two children who relapsed following BMT in first remission and one child transplanted in relapse following unsuccessful reinduction chemotherapy remain alive and disease-free. When sub-divided on the basis of consolidation treatment given in second remission there were no significant differences in survival between groups on Mantel-Byar analysis but one of three surviving children given chemotherapy only suffered a second relapse and is alive following a mismatched family donor BMT in relapse. The two Figure 3 AML 10: disease-free survival from 2nd remission.
remaining children given chemotherapy only include one with standard risk AML at diagnosis with a first remission of 453 days who remains in second remission at 5 years, and one with good risk disease (inversion of chromosome 16) with first remission under 6 months who is in third remission 3 years following further chemotherapy for a second relapse. Accordingly, the data for those children given chemotherapy alone remain unstable. There was a marginally significant difference in relapse risk between transplanted and nontransplanted patients (P = 0.04, Table 3 ). Relapse remained the primary cause of death, but 13 children died of treatment related toxicity -eight due to sepsis, and one each from cardiac failure, haemorrhage, respiratory failure, liver failure and multiple causes. Eight of these toxic deaths followed a bone marrow transplant. Among children treated by chemotherapy only there were six further relapses and five toxic deaths before the median time from second remission to BMT of 67 days. The second remission rate, overall survival, disease-free survival, and relapse rate were affected by length of first remission and risk group (all P Ͻ 0.01) (see Tables 4 and 5) . Risk group and length of first remission were highly correlated, ie good risk children tended to have longer first remissions (Tables 6 and 7 ) and on bivariate analysis length of first remission (P = 0.002, P = 0.003 for patients where reinduction was attempted) was of greater significance than risk group (P = 0.04, P = 0.1 for patients where reinduction was attempted) for remission rate and for overall survival (length of first remission controlling for risk group: P = 0.0003, P = 0.0005 in reinduction attempts; risk group controlling for length of first remission P = 0.06, P = 0.1 in reinduction attempts). The effect of length of first remission on survival and disease-free survival is shown in Figures 4 and 5 .
Discussion
Despite improved first-line therapy for AML in childhood, relapse remains the primary cause of treatment failure irrespective of whether therapy is by intensive chemotherapy alone or combined with bone marrow transplantation, with relapse rates of 30-50% in modern studies. 3, [10] [11] [12] [13] [14] [15] In AML 10 the bone marrow was the only site of relapse in 82% of cases, and central nervous system relapse was very uncommon following a protocol without routine cranial irradiation, indicating that radiotherapy should be reserved for children with frank CNS disease. Survival following a first relapse has been poor and in this study, the overall survival following relapse was 24% at 3 years, similar to other reports, 7, [16] [17] [18] [19] [20] [21] but 18% of children received palliative care only, and there were subgroups of patients with a high chance of achieving prolonged second remissions. The length of first remission was of primary importance in determining the likelihood of successful retreatment, with poor response rates for children relapsing within 1 year of first remission, and this finding confirms several other reports of outcome, predominantly in adults. In AML 10, three risk groups were identified, but these risk groups had only a weak independent effect on the rate of second remission, and on survival as length of first remission and risk group were strongly correlated, and on bivariate analysis length of first remission was the more important factor. Creutzig et al 7 reported similar results following relapse in children treated on BFM protocols, with 21% overall survival at 5 years. Length of first remission affected prognosis, with a 3 year survival of 12% for children relapsing before 18 months, compared with 47% for later relapses. Keating et al Six of these deaths (plus five early 2nd relapses) occurred within 40 days of second remission, the median time to BMT. Small numbers and lack of randomised allocation to treatments precludes conclusions from these data, but indicates the need for appropriate clinical trials. Details on reinduction therapy unavailable for three children, one of whom went into second remission. **P Ͻ 0.001; ***P Ͻ 0.0001. Details on reinduction therapy unavailable for three children and details of risk group unavailable for a further five patients, three of whom went into second remission. *P Ͻ 0.01; **P Ͻ 0.001; ***P Ͻ 0.0001. identified duration of first remission, age, and serum lactate dehydrogenase (LDH), but not cytogenetics, as significant factors influencing second remission rate in adults, and duration of first remission, age, serum bilirubin, percentage blasts and promyelocytes in the blood, and serum alkaline phosphatase as factors affecting survival. Estey 6 described a simplified strategy based on length of first remission, and previous treatment to guide approaches to salvage chemotherapy, suggesting that individuals with relapse within 1 year of first CR had little chance of either remission or survival with conventional regimens and should be considered eligible for phase I and II studies. Thalhammer et al 5 described the outcome of 168 patients retreated following a first relapse -39% achieved second remission, and the probability of second remission and survival were affected by the length of first remission with a disease-free survival of 35% at 3 years for those with a first 29 Table 7 Effects of length of first remission (CR1) and risk group on overall survival (%) at 3 years from first relapse 
Figure 5
AML 10: disease-free survival from 2nd remission by duration of 1st remission. remission of over 1 year, compared with 0% for patients with shorter remissions. The overall survival for the whole group was 24% at 3 years.
The possibility of improving outcome for children with early relapse is severely limited with current therapies, as in our study only 36% of patients with relapse in the first year entered second remission, and survival was 11% at 3 years. Over 60% of all relapses occurred within 1 year from first remission, and there is no evidence that retreatment with standard therapies will help the majority of these children, who should be considered for novel therapies. For children with initial remissions of over 1 year, however, response and survival rates were more encouraging, justifying further intensive therapy in this group.
It is not possible to reliably assess the relative benefits of different chemotherapy regimens for reinduction from this study, nor to compare different strategies for consolidation due to the small numbers and the non-randomised selection of treatments. However, intensive regimens with or without anthracyclines appeared similarly effective, and this has important implications for the avoidance of cardiotoxicity in children with high cumulative exposure to anthracyclinescardiotoxicity was a cause of morbidity and mortality in AML 10 where children received 300 mg/m 2 of daunorubicin and 50 mg/m 2 of mitoxantrone, 3 and avoidance of further anthracyclines and/or strategies for cardioprotection should be employed wherever possible. Survival rates of 20-40% have been reported in selected patients receiving consolidation with intensive chemotherapy, ABMT or BMT in second remission, [17] [18] [19] [22] [23] [24] [25] [26] [27] [28] and similar outcomes were observed both in this study, and by the BFM group. 7 Children who received chemotherapy alone in our study had significantly shorter first remissions than those treated by BMT, and 11/18 of this group relapsed again or died of toxicity prior to the median time to transplant indicating selection bias between treatment groups. These data emphasise the need for proper randomised studies to address issues of salvage chemotherapy and the role of different types of bone marrow transplantation, and due to the small numbers of children with AML international collaborative studies are crucial to allow these issues to be appropriately addressed.
